OTCMKTS:AGNPF Algernon Pharmaceuticals (AGNPF) Stock Price, News & Analysis $0.05 0.00 (0.00%) As of 07/25/2025 Add Compare Share Share Stock Analysis Stock AnalysisChartHeadlinesSEC FilingsShort InterestBuy This Stock About Algernon Pharmaceuticals Stock (OTCMKTS:AGNPF) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get AGNPF alerts:Sign Up Key Stats Today's Range$0.05▼$0.0550-Day Range$0.04▼$0.0752-Week Range$0.04▼$0.10VolumeN/AAverage Volume18,724 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Algernon Pharmaceuticals Inc. operates as a clinical stage pharmaceutical development company. It focuses on the areas of non-alcoholic steatohepatitis, chronic kidney disease, inflammatory bowel disease, idiopathic pulmonary fibrosis, chronic cough, pancreatic and small cell lung cancer, and acute lung injury in Canada and Australia. The company's pipeline includes Ifenprodil, which is in Phase 2b clinical trial for the treatment of idiopathic pulmonary fibrosis and chronic cough; repirinast, which is in Phase 1 clinical trial for the treatment of chronic kidney disease; and N,N-Dimethyltryptamine, which is in Phase 1 clinical trial for the treatment of strokes and traumatic brain injuries. The company was formerly known as Breathtec Biomedical, Inc. and changed its name to Algernon Pharmaceuticals Inc. in July 2015. Algernon Pharmaceuticals Inc. was incorporated in 2015 and is headquartered in Vancouver, Canada. Read More Receive AGNPF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Algernon Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address AGNPF Stock News HeadlinesAlgernon Pharmaceuticals closes private placement to fund Alzheimer's clinic initiativeJuly 25 at 8:31 AM | proactiveinvestors.comAlgernon Announces Closing of the Private Placement FinancingJuly 24 at 5:02 PM | globenewswire.comHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 trillion vault of untapped American wealth. Former CIA advisor Jim Rickards calls it the “Old Testament Wealth Code” — and says it could transform your financial future. He’s revealing everything in a new presentation.July 26 at 2:00 AM | Paradigm Press (Ad)Algernon Announces Amended Terms for Private Placement and Closing of the First Tranche totaling $621,000June 30, 2025 | globenewswire.comAlgernon Announces $1M Private PlacementMay 27, 2025 | globenewswire.comAlgernon closes NoBrainer acquisitionMay 23, 2025 | msn.comAlgernon Closes NoBrainer Imaging Centers, Inc. AcquisitionMay 22, 2025 | financialpost.comFAlgernon Closes NoBrainer Imaging Centers, Inc. AcquisitionMay 22, 2025 | globenewswire.comSee More Headlines AGNPF Stock Analysis - Frequently Asked Questions How have AGNPF shares performed this year? Algernon Pharmaceuticals' stock was trading at $0.0463 at the beginning of 2025. Since then, AGNPF shares have increased by 4.8% and is now trading at $0.0485. When did Algernon Pharmaceuticals' stock split? Shares of Algernon Pharmaceuticals split on Friday, March 3rd 2023.The 4-1 split was announced on Friday, March 3rd 2023. The newly issued shares were issued to shareholders after the closing bell on Friday, March 3rd 2023. An investor that had 100 shares of stock prior to the split would have 400 shares after the split. How do I buy shares of Algernon Pharmaceuticals? Shares of AGNPF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today7/26/2025Next Earnings (Estimated)7/28/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Biotechnology Sub-IndustryPharmaceutical Products Current SymbolOTCMKTS:AGNPF CIK1642178 Webalgernonpharmaceuticals.com Phone604-398-4175FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for August 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free Report This page (OTCMKTS:AGNPF) was last updated on 7/26/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump's 2025 Economic Revolution Is Here Are Your Retirement Savings Ready?Time is short. Trump's reforms may be coming fast—and the financial system roller coaster may be a ride that y...Create New Advertiser | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…GoldCo Precious Metals | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Algernon Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Algernon Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.